Founded in 1979 and headquartered in Natick, Massachusetts, LANCO is a leading medical technology company in the world.
In 1997, LANCO entered China and set up branches and R & D centers in DIDU, Mordor and Yangcheng. The company''s headquarters in China is located in Mordor.
LANCO''s core business areas in China are cardiac intervention, cardiac rhythm management and electrophysiology, structural heart disease, endoscopic intervention, respiration, peripheral and tumor intervention, etc.
As the world''s leading provider of innovative medical solutions, LANCO is committed to long-term investment in innovative R & D.
LANCO has more than 13000 products and has obtained more than 16000 authorized patents worldwide. In 2013, LANCO''s R & D investment reached US $861 million, making it one of the largest medical device companies in the world.
In the process of the rise of cardiovascular intervention surgery in China, Boke company has made huge excess profits.
Their ambition is more than that. Both Johnson & Johnson and Medtronic are one step ahead of LANCO in business promotion and technology.
Therefore, LANCO has recently invested a lot of money to produce consumables for interventional minimally invasive treatment of mitral regurgitation, which has entered the phase IV clinical stage.
If this business is promoted, LANCO is confident to become the leader of cardiac intervention consumables in the United States and even the world.
……
……
Jack Jones actually signed the document in the CEO''s office at LANCO headquarters in Natick, Massachusetts.
Jack Jones is upset that the company''s recent research is in trouble.
The research on high-value consumables for mitral valve clipping under interventional surgery is the huge profit growth point of LANCO company and the hope of the company.
From the establishment of the project in 2002 to the approval of FDA in 13 years, it has gone through thousands of hardships and invested a huge amount of money.
One week after approval, Professor saibalkar, deputy director of cardiovascular intervention center of Sida Sinai Medical Center, completed the first mitral valve clipping in the United States for the treatment of life-threatening heart valve diseases.
All this seems to be so perfect. Continuous technological progress is the best way to obtain excess profits, which no one knows.
However, technological progress is so difficult that LANCO reluctantly supports the excess return of high-value consumables with the circular intervention of the top three in the world.
It was thought that after 13 years of FDA approval, mitral valve clamping surgery could be successfully promoted all over the world, but the key to the final operation was stuck in technology.
The consumables developed by LANCO are mainly used for mitral regurgitation patients with mitral regurgitation located in A2P2 area, and there is no obvious calcification or split valve in these two areas.
The latter is not difficult, but it requires A2P2 reflux, which limits most operations.
Dr. Saibal Kar, a cardiac intervention expert at the Sinai Medical Center in West Dakota, USA, is the completer of the first clinical mitraclip in the United States and works closely with LANCO.
He completed 133 mitraclips in 2017, ranking first in the world.
It is the number one in the world that gives LANCO a great headache.
The minimally invasive surgery for mitral regurgitation, which cost a lot of money, has only 133 doctors in the world!!!
LANCO can''t stand this kind of thing.
The technology department wants to improve the technology and strive to make all patients with mitral insufficiency suitable for surgery. But a few years later, the surgical indications are still limited to mitral insufficiency in A2P2 area.
According to the current situation, the huge research cost can not be recovered, let alone the excess profit.
This is a headache that every pharmaceutical enterprise and consumables company must face.
It is often said that multinational pharmaceutical enterprises have failed because of the failure of a research project with good prospects and huge investment.
Although LANCO is not going to go bankrupt, the situation they are facing is still not optimistic.
The company has made many adjustments to this, and the technology department seems to be working hard to improve it. It is looking for world-famous circulation interventional surgeons to study it together.
However,
The results were disappointing.
"Dong Dong ~"
There was a knock at the door.
"Mr. Jones, there''s a new mail," said Jack Jones''s assistant politely, bowing slightly when the door opened.
"Whose? What?" Jack Jones didn''t look up. He was reviewing the results of the new quarter.
"It''s an email from Dr. Wu of Massachusetts General Hospital..."
"No matter what he said, he refused," said SEB Carr coldly.
The assistant hesitated for a moment. He didn''t know why the world''s top doctors invited by the company several times sent emails, but Mr. Jack Jones refused without thinking.
After hesitating, the assistant bowed away.
Just as the door was about to close, he couldn''t help saying, "Mr. Jones..."
"Why?" Jack Jones looked up and held his glasses. There was already an expression of unhappiness in his eyes.
"Don''t you really look at the mail?"
"No, I''m busy." Jack Jones said nothing else and continued to look down at the results.
"Mr. carr... Wu said he could do total mitral valve clipping." the assistant couldn''t help saying.
"Refuse him..." just after half a sentence, SEB Carr suddenly raised his head in surprise and looked at his assistant, "what did you just say? What did Wu say in the email?"
"Wu said in his email that he had found a way to perform total mitral valve clipping," said Jack Jones''s assistant.
"..." Jack Jones was stunned.
The so-called total operation is an operation that can be applied to all patients with mitral insufficiency. Unlike the dilemma faced by the company, it can only treat patients with mitral insufficiency in A2P2 area.
Full operation!
This is what LANCO has been looking for!
In front of Jack Jones, the gold was shining, as if it were the gold rush era. He found a river full of gold sand alone.
"Print out the mail and give it to me right away." Jack Jones seems to have forgotten what he said before.
"Yes, Mr. Jones." his assistant bowed away.
A few minutes later, Jack Jones looked at the mail word by word.
The young man said that he had passed the animal experiment and could complete the operation of total mitral insufficiency. As long as LANCO agrees, we can cooperate.
Of course, Wu directly explained what he needed in the email.
The intervention consumables of congenital heart disease are not difficult for Boko. Although the selling price is high, the cost price is very low.
What was most unacceptable to Jack Jones was that Wu said he would not come to Natick and asked Boko to set up the research institution in an unknown place.
Agree or disagree, this is a question.
Such a big thing must pass through the board of directors, and Jack Jones finally made such a decision.